Skip to content

Remainder of 2026 at other companies

ADMA Biologics logo
ADMA BiologicsADMA

Other financials

Income statement

See full
Revenue$65.8M+40.5%
Gross profit$33.7M+336%
Operating income-$2.2M+95.6%
Net income-$3.7M+87.5%
EPS (diluted)-$0.02+90.5%

Balance sheet

See full
Cash & equivalents$165.9M-41.8%
Total debt$270.9M-17.1%
Total equity$211.6M-29.6%
Total assets$713.2M-25.7%

Cash flow

See full
Operating cash flow$8.7M+192%
CapEx$4.4M-1.4%
Free cash flow$4.2M+130%

Valuation

See full
Market cap$902.74M+204%
Enterprise value$1.01B+198%
P/S4.4×+3.2×

Profitability

See full
Gross margin29.3%-8.0pp
Operating margin-82.2%-16.6pp
Net margin-51.1%-9.9pp
FCF margin-25.7%

Returns & leverage

See full
Return on equity-40.8%-4.0pp
Debt / equity1.3×+0.2×
Current ratio5.9×-0.1×

Where this comes from

Reported directly by Maravai LifeSciences Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear.

The official record: Maravai LifeSciences Holdings, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Maravai LifeSciences Holdings, Inc.'s remainder of 2026.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Maravai LifeSciences Holdings, Inc.'s remainder of 2026?
Maravai LifeSciences Holdings, Inc. (MRVI) reported remainder of 2026 of $4.08M in Q1 2026.
How has Maravai LifeSciences Holdings, Inc.'s remainder of 2026 changed year-over-year?
Maravai LifeSciences Holdings, Inc.'s remainder of 2026 decreased by 0.0% year-over-year, from $4.08M to $4.08M.